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Abstract 
A substantial number of individuals have long-lasting adverse effects from a traumatic brain injury (TBI). 
Depression is one of these long-term complications that influences many aspects of life. Depression can 
limit the ability to return to work, and even worsen cognitive function and contribute to dementia. The 
mechanistic cause for the increased depression risk associated with a TBI remains to be defined. As TBI 
results in chronic neuroinflammation, and priming of glia to a secondary challenge, the inflammatory 
theory of depression provides a promising framework for investigating the cause of depression following a 
TBI. Increases in cytokines similar to those seen in depression in the general population are also increased 
following a TBI. Biomarker levels of cytokines peak within hours-to-days after the injury, yet pro-inflam-
matory cytokines may still be elevated above physiological levels months-to-years following TBI, which 
is the time frame in which post-TB! depression can persist. As tumor necrosis factor a and interleukin 1 
can signal directly at the neuronal synapse, pathophysiological levels of these cytokines can detrimentally 
alter neuronal synaptic physiology. The purpose of this review is to outline the current evidence for the 
inflammatory hypothesis of depression specifically as it relates to depression following a TBI. Moreover, 
we will illustrate the potential synaptic mechanisms by which tumor necrosis factor a and interleukin 1 
could contribute to depression. The association of inflammation with the development of depression is 
compelling; however, in the context of post-TB! depression, the role of inflammation is understudied. This 
review attempts to highlight the need to understand and treat the psychological complications of a TBI, 
potentially by neuroimmune modulation, as the neuropsychiatric disabilities can have a great impact on 
the rehabilitation from the injury, and overall quality of life. 
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Introduction 
Traumatic brain injury (TBI) is a public health crisis, which 
by conservative estimates, affects 1. 7 million Americans each 
year (National Center for Injury Prevention and Control, 
2003; Faul et al., 2010) . Consequences of brain injury are 
known to increase in prevalence proportionally to the se-
verity of the TBI and with increasing instances of TBI. Some 
of these consequences include physical disability, memory 
impairments, and mood disorders (Blennow et al., 2016). In 
addition, factors such as age at the time of injury, sex, and 
genetic predisposition are associated with increased long-
term complications from the TBI (Blennow et al., 2016). 
people with a mild TBI that have symptoms unresolved for 
longer than three months, the individuals are diagnosed 
with post-concussive syndrome. The symptoms associated 
with the post-concussive syndrome are varied and sub-
jective: including sleep disturbances, headache, and mood 
disorders, such as anxiety, irritability, and depression (Blen-
now et al., 2016). Repeated brain injuries can increase the 
prevalence and severity of post-concussive symptoms and 
may lead to a neurodegenerative condition called chronic 
traumatic encephalopathy (CTE), which is a pathologically 
diagnosed disease. 
As many as 90% of TBis are classified as concussions, or 
mild TBI (Blennow et al., 2016). The vast majority of the 
time (80-90%), symptoms of the mild TBI will resolve with-
in the first two weeks after the injury (Blennow et al., 2016). 
Even with the resolution of symptoms in the vast majority 
of people following a mild TBI, there is compelling evidence 
that progressive brain atrophy, as well as cognitive dysfunc-
tion, continue after a mild TBI (Gardner and Yaffe, 2015; 
Rabinowitz et al., 2015; Theadom et al., 2018). For those 
Memory impairments, sleep disturbances, headache, and 
mood disorders caused by TBI are highly interrelated. Treat-
ment in one area following TBI may be beneficial in improv-
ing other symptoms. For example, treating depression can 
reduce memory impairments, overall disability, and improve 
quality of life (Kumar et al., 2018). Among the various cog-
nitive disturbances following mild TBI, depression severity 
is strongly associated with overall disability following a mild 
TBI (Mac Donald et al., 2017) and is more common in peo-
ple that suffered a TBI compared to the general population 
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(Blennow et al., 2016). 
In general, responsiveness to depression treatment is typ-
ically inconsistent (Belmaker and Agam, 2008), and may be 
even more so for depression associated with a TBI (Blennow 
et al., 2016) . For example, while prior anecdotal evidence 
has suggested that depression in individuals with a history 
of TBI are responsive to anti-depression medication, recent 
results show this may not always be the case. Specifically, 
a recent randomized controlled trial found that a selective 
serotonin reuptake inhibitor (SSRI), Sertraline (trade name: 
Zoloft), was no more effective than placebo in people with 
depression following a TBI (Fann et al., 2017). This single 
trial does not prove, or even suggest, that individuals with 
depression and a history of TBI will not benefit from an 
SSRI or other anti-depression medication. It is possible that 
depression associated with TBI is more likely to be treat-
ment-resistant, but to the best of our knowledge, this associ-
ation has not been tested. 
Depression does not arise from a single known pathogenic 
mechanism (Belmaker and Agam, 2008). A prior history of 
mood disorder and other comorbidities, such as substance 
abuse, psychosocial factors, and cardiovascular disease may 
contribute to the risk of developing depression following a 
TBI (Blennow et al., 2016). However, without a complete 
understanding of the pathophysiological mechanism(s) that 
lead to depression following TBI, targeted disease-modify-
ing therapies cannot be developed. 
While a specific mechanism has not been established, ac-
cumulating evidence indicates that inflammatory pathways 
may contribute to the development of depression, at least 
in a subset of patients (Miller and Raison, 2016). Given that 
inflammation can persist for years after a TBI (Ramlack-
hansingh et al., 2011; Coughlin et al., 2017), it is logical to 
speculate that the chronic low-grade inflammation seen after 
a TBI could be mechanistically linked to the high rates of de-
pression following a TBI. In recent years, a limited number 
of studies have provided intriguing preliminary evidence of 
a link between TBI-induced inflammatory biomarkers in the 
cerebrospinal fluid (CSF) and increased odds of developing 
depression (Juengst et al., 2015), as well as an increased asso-
ciation with suicidal endorsement (Juengst et al., 2014), and 
post-traumatic stress disorder (PTSD) (Speer et al., 2018). 
The objective of this review is to discuss the current ev-
idence for the inflammatory hypothesis of depression, as 
it relates to post-TBI depression. We will first describe the 
evidence for both acute and chronic inflammatory cytokine 
changes following a TBI. We will then summarize the prev-
alence of depression following TBI. Linking cytokines and 
depression, we will then provide a general overview of the 
inflammatory hypothesis of depression. Then focusing on 
the IL-1, and TNFa pathways, two of the cytokines which 
have been most consistently shown to be dysregulated by a 
TBI, we will summarize the potential cellular and molecular 
mechanisms of those cytokines that may contribute to post-
TBI depression. As a whole, the concept of anti-inflamma-
tory therapy for depression is compelling, but largely unex-
plored, particularly in the context of post-TB! depression. 
By summarizing the state of the field, we hope to stimulate 
inquiries into the inflammatory theory of post-TB! depres-
sion, as a promising area of treatment for the chronic com-
plications of TBI. 
Cytokine Changes Associated With a TBI 
The inflammatory response to a TBI has been the subject of 
many in-depth reviews, and we recommend the following 
reviews for readers who would like a more general overview 
of neuroinflammation following TBI (Witcher et al., 2015; 
Burda et al., 2016; Faden et al., 2016; Hellewell et al., 2016; 
Loane and Kumar, 2016; Jassam et al., 2017; Simon et al., 
2017; Ziebell et al., 2017; Kokiko-Cochran and Godbout, 
2018). The goal of the current review is to highlight the 
function of inflammatory cytokines as a critical mediator of 
the inflammatory effects on neuronal dysfunction as it re-
lates to post-TB! depression, and as such we will not provide 
a general overview of neuroinflammation. 
Cytokines are a category of signaling proteins that act 
via binding to specific receptors. The dominant effects of 
cytokines occur by cell-to-cell interaction in the local tis-
sue environment via paracrine signaling, or even acting on 
the releasing cell in an autocrine manner (Gulati, 2009). 
Chemokines, which are a subclass of cytokines, in contrast, 
have more global effects with important endocrine functions 
such as establishing gradients to chemoattract cells to the 
appropriate target. 
Neurotransmitters were once thought to only act in the 
nervous system and cytokines were thought to be restricted 
to the immune system; however, there is now resounding 
evidence that both neurotransmitters and cytokines are 
used in both the nervous and immune systems (Liu and 
Quan, 2018). For example, in the brain, interleukin (IL)-
1 is largely produced by microglia and astrocytes (Liu and 
Quan, 2018); interestingly, the receptor for IL-1 is found on 
endothelial cells and neurons (Liu and Quan, 2018). Recent 
evidence suggests that there is heterogeneity in the class of 
neurons that express the receptor for IL-1 (Liu and Quan, 
2018). Thus, there is an exciting possibility that expression 
of different cytokine receptors may define unique subtypes 
of neurons and provide an additional level modulatory in-
formation at the level of synaptic transmission. 
Cytokines historically have been linked to the innate and 
adaptive immune system where they are involved in defense 
against pathogens (Gulati, 2009). In the healthy organism, 
cytokines are produced at very low levels, but in response to 
activating stimulus (i.e., pathogen, or tissue damage) levels 
of cytokines can be rapidly induced to levels greater than a 
100-fold of that found at the basal condition. This property 
of rapid and robust induction has caused cytokines to be a 
very active area for biomarker research, as we will describe 
in the following paragraph. The dramatic increase in cyto-
kines after an activating stimulus is limited in time as high 
levels of circulating cytokines, such as in sepsis, can be fa-
tal. The mechanisms for temporally and spatially limiting 
the cytokine response include, for example, unstable RNA 
(Stumpo et al., 2010; Vlasova-St Louis and Bohjanen, 2014), 
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short half-life of the cytokine proteins, anti-inflammatory 
cytokines (i.e., IL-4 and IL-10), receptor internalization, 
degradation or shedding, decoy receptors (IL-1R2), and 
receptor antagonists (IL-Ira) (Garlanda et al., 2013). Thus, 
cytokines whisper to neighboring cells when conditions are 
good, but when things are not good, they can also yell. 
To measure cytokine changes in people after a TBI four 
approaches have been used, including measuring cytokines 
in blood, cerebrospinal fluid (CSF), microdialysate, and 
biopsy or postmortem brain tissue. Blood biomarker mea-
surements are the least invasive approach, with levels of 
cytokines determined in either serum, plasma, and in some 
instances by stimulating circulating immune cells with a 
mitogen. In the case of moderate-to-severe TBI, CSF that 
would otherwise be discarded during the management of 
intracranial pressure is collected for biomarker assays. Ce-
rebral microdialysis probes are capable of sampling the local 
brain parenchymal concentrations of cytokines, and other 
molecules, but must be neurosurgically implanted (Helmy et 
al., 2011). 
A few technical considerations must be taken into account 
when interpreting cytokine biomarker changes after an inju-
ry. The sensitivity of the assay used to measure the cytokines 
can affect the ability to detect low levels of cytokines. In our 
own experience, we have found that multiplex cytokine kits 
from different companies or even new versions of the kit 
from the same company can find different results concern-
ing which cytokine is most abundantly expressed after an 
injury and if certain cytokines can be detected or not. Differ-
ences in processing the samples can result in degradation of 
the cytokines. How often the CSF is sampled, for example, 
can affect the ability to detect cytokine changes after TBI 
(Shore et al., 2004). Microdialysis can measure tissue levels 
of cytokines, but the probe itself can induce inflammation, 
and the location of the probe in relation to the areas of the 
brain that are injured can influence the results (Helmy et al., 
2009). Regardless of which method is used to measure cyto-
kine levels, there is clear evidence that cytokines are elevated 
following a TBI, as we describe below. 
Only a few studies have reported cytokine changes in 
people following mild TBI (Mukherjee and Mobry, 1979; 
Ghezzi et al., 1996; Sharma et al., 2017), while the majority 
of studies measuring cytokine changes after injury have 
been done following moderate-to-severe TBL An interest-
ing recent study found in a military population that a mild 
TBI was associated with elevated IL-6 and tumor necrosis 
factor a (TNFa) in plasma. Intriguingly, the elevated IL-6 
and TNFa were associated with PTSD and depression in this 
military population (Devoto et al., 2017). In multiple studies, 
a moderate-to-severe TBI was found to cause a significant 
elevation of IL-6 with the peak of the response occurring 
within the first day, and levels returning to baseline within 
the first week (Kossmann et al., 1995; Bell et al., 1997a, b; 
Pleines et al., 2001; Park et al., 2002; Hayakata et al., 2004; 
Shore et al., 2004; Chiaretti et al., 2005, 2008; Buttram et al., 
2007; Frugier et al., 2010; Helmy et al., 2011; Mellergard et 
al., 2011; Roberts et al., 2013; Yan et al., 2014a; Aisiku et al., 
2016; Kumar et al., 2016; Nwachuku et al., 2016). TNFa was 
found to be significantly elevated in some studies ( Otto et 
al., 2000; Hayakata et al., 2004; Buttram et al., 2007; Frugier 
et al., 2010; Helmy et al., 2011; Roberts et al., 2013; Juengst 
et al., 2014; Yan et al., 2014a), and no significant difference 
was found in others (Helmy et al., 2011; Aisiku et al., 2016; 
Kumar et al., 2016; Nwachuku et al., 2016). Similarly, IL-lb 
was found to be elevated in some studies (Park et al., 2002; 
Chiaretti et al., 2005; Shiozaki et al., 2005; Buttram et al., 
2007; Chiaretti et al., 2008; Helmy et al., 2011; Mellergard et 
al., 2011; Roberts et al., 2013; Nwachuku et al., 2016), while 
not in others (Frugier et al., 2010; Aisiku et al., 2016; Kumar 
et al., 2016) 
The increases in cytokine levels occurring acutely after 
injury, as measured in the clinical biomarker studies, have 
been shown to correlate with injury severity, and can be 
predictive of functional recovery (Kumar et al., 2016; Nwa-
chuku et al., 2016). These properties as a biomarker of injury 
severity do not provide direct evidence that these acute cyto-
kine surges seen after the injury are themselves detrimental 
to long-term recovery. The increase in cytokines is likely 
proportional to the damage caused by the primary injury. 
While the clinical literature is limited on the use of anti-cy-
tokine therapy as a neuroprotective following TBI, there is 
a fairly extensive preclinical literature showing inhibiting 
cytokines acutely after injury can be protective (Simon et 
al., 2017). To use an example from our own work, we have 
found that a small molecule inhibitor of cytokine overpro-
duction was able to improve functional recovery in a learn-
ing and memory task following an experimental brain injury 
in mice (Bachstetter et al., 2015). 
Prevalence of Depression Following TBI 
The compelling relationship of TBI with cognitive impair-
ment and dementia has led to a substantial focus investi-
gating this association by the clinical and scientific com-
munities. Significant psychological disabilities, including 
aggression, anxiety, substance abuse and depression, as well 
as, physical complications including pain, motor, and bal-
ance impairments are also complication of a TBI. Rarely do 
the cognitive, psychological, and physical complications of a 
TBI occur in isolation (Kumar et al., 2018). For more infor-
mation on this topic, please refer to an excellent recent re-
view and meta-analysis that illustrates the interrelationship 
of post-traumatic depression, and other common secondary 
complications of a moderate-to-severe TBI, such as cogni-
tive function and pain (Kumar et al., 2018). 
Depression is one of the common psychological sequelae 
of TBI, with as high as 56% of individuals having symptoms 
of depression at 10-week post-injury (Singh et al., 2018) . 
Following a moderate-to-severe injury, the cumulative rate 
of major depressive disorder during the first year was found 
to be 53%, compared to the rate of major depressive disor-
der in the general population around 7% (Bombardier et 
al., 2010). Further, when studies are limited to concussions, 
still up to 22% of people develop depression during the 
first 6-months after the injury (Max et al., 2012). A history 
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of concussion is associated with 3.3-fold greater risk for a 
diagnosis of depression in adolescents (Chrisman and Rich-
ardson, 2014), as well as a 2-fold increase in the elderly (Al-
brecht et al., 2015). On top of single injury risk, the risk for 
developing depression is greatly enhanced by the number of 
concussions that a person sustains. The relative risk of devel-
oping depression increases from 1.5 to 3 when individuals 
report less than 3 versus 3+ concussions ( Guskiewicz et al., 
2007). Injury severity, number of injuries, age at the time of 
injury, and other factors influence the relative likelihood of 
post-TBI depression, but few are spared from the risk that a 
TBI could contribute to depression. 
Like depression in the general population, post-TBI 
depression has been found to affect many aspects of life. 
Global disability, which reflects both work and non-work 
related disability, was found at 6-12 months post-injury to 
be significantly correlated with depression severity in a re-
cent study of combat-related concussive TBis in US military 
personnel (Mac Donald et al., 2017). In civilians, those in-
dividuals that can return to work after the mild TBI, report 
that they are less productive and more error prone than be-
fore the injury (Silverberg et al., 2018). This reduction in job 
performance was associated with depression but not bodily 
pain (Silverberg et al., 2018), indicating that something spe-
cific about the mechanism of depression following injury is 
affecting other cognitive functions. A double-blind, place-
bo-controlled, randomized clinical trial provided promising 
evidence that an SSRI, Sertraline, could reduce the onset of 
depression following a TBI when Sertraline was given during 
the first 6 months after injury (Jorge et al., 2016). An inde-
pendent double-blind, placebo-controlled study did not find 
a significant effect of Sertraline on major depression after a 
TBI; however, the study did find that cognitive function was 
improved (Fann et al., 2017). More research is clearly war-
ranted to understand the mechanism ofpost-TBI depression 
as the evidence strongly suggest a critical role of depression 
in the squeal of TBI, including disability, work productivity, 
and cognitive function. 
Inflammatory Theory of Depression 
Could depression be an inflammatory-mediated and evolu-
tionarily conserved mechanism to TBI? A recent review pa-
per by Drs. Miller and Raison provided a compelling answer 
to this question (Miller and Raison, 2016). A primary tenet 
of their treatise is that inflammation signals to the organism 
to decrease activity, to allow time to fight infection, heal 
from wounds, and avoid further pathogen exposure. Argu-
ably, everyone has experienced an inflammatory state of de-
pression, typically during cold and flu season. This response 
is not limited to acute inflammatory responses but carries 
over to chronic inflammatory diseases. Indeed, sickness 
behavior shares many hallmarks of major depressive disor-
der, such as social withdrawal, and anhedonia (Dantzer et 
al., 2008; Miller and Raison, 2016). The difference between 
chronic inflammatory disease and acute inflammation as-
sociated with infection and their link with depression may 
involve the mechanisms of clearing the infection. The sick-
ness behavior associated with a viral infection and its con-
comitant increase in inflammation, for example, is transient. 
Depressive-like symptoms resolve as the infection clears. In 
the case of aging, cardiovascular disease, stress, Alzheimer's 
disease, and TBI, however, the stimulus that is inducing the 
proinflammatory state and the linked depressive-like symp-
toms does not readily clear like a viral infection, instead a 
protracted or even chronic low-grade response remains. 
While the levels of inflammatory cytokines, for example, will 
be much lower in the chronic disease states, than following a 
serious infection, they are nevertheless elevated above phys-
iological levels and thus should be considered as pathophys-
iological. Evidence in support of the involvement of inflam-
mation in depression comes from three main observations, 
as described below. 
The first line of evidence supporting the inflammatory 
theory of depression is correlative and relies on the presence 
of elevated cytokines in the blood of depressed individuals 
compared to healthy controls. While correlative, the results 
are nevertheless impressive, as summarized in a number 
of excellent reviews and meta-analyses (Kohler et al., 2017, 
2018; O'Brien et al., 2007; Leighton et al., 2018). Specifically, 
a meta-analysis of 82 studies showed that peripheral levels 
of numerous cytokines and chemokines, including IL-6 and 
TNFa, were elevated in people with major depressive dis-
order compared to healthy controls (Kohler et al., 2017). A 
subsequent meta-analysis furthered the association between 
cytokines and depression as they found that the use of an-
ti-depression medication was associated with a reduction 
in peripheral inflammatory cytokine levels (Kohler et al., 
2018). It has also been found that increased proinflamma-
tory molecules in systemic circulation are associated with 
reduced efficacy of anti-depressants (O'Brien et al., 2007; 
Leighton et al., 2018). While the evidence is persuasive, a 
number of questions are raised, the most critical being; how 
is the depression leading to elevated systemic inflammation, 
and how does systemic inflammatory response affect the 
neurocircuitry to induce depressive behaviors? 
In the review by Drs. Miller and Raison, they propose 
three routes to transmit inflammatory signals between 
the periphery and the central nervous system (CNS): 1) a 
humoral route where cytokines, chemokines, and other in-
flammatory molecules move back and forth from the blood 
and brain, potentially through circumventricular organs; 2) 
a cellular route where activation of monocytes/macrophages 
by cytokines and chemokines leads to the recruitment of 
cells to the brain; 3) a neural route where peripheral nerves, 
such as the vagus, stimulate directly on the immune cells in 
the bone marrow and spleen, for example, to activate an im-
mune response (Miller and Raison, 2016). 
In the context ofTBI, the elevation of cytokines is likely to 
first occur locally within the central nervous system by reac-
tive microglia/macrophages and astrocytes (Figure I). The 
CNS inflammation or the primary damaged caused by the 
TBI could also alter one of the bidirectional routes of com-
munication between the periphery and the CNS, leading to 
a chronic dysregulation of the neuroinflammatory response. 
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Regardless of the source of the inflammation, if elevated 
cytokines are seen in the blood chronically after TBI, this 
could be an indicator of individuals that should be evaluated 
for depression and may predict the success of treatment to 
reduce the depression. 
The second line of evidence comes from the therapeutic 
use of cytokines. Type I interferons used in the treatment 
of hepatitis and multiple sclerosis are strongly associated 
with the development of depression, with as much as 80% of 
patients on Type I interferon therapy developing depression 
(Raison et al., 2005). Not all individuals are equally suscepti-
ble to this interaction; for example, patients that have a prior 
history of mood disturbances are at a greater risk for devel-
oping depression with Type I interferon treatment (Raison 
et al. , 2005) . Similarly, in TBI having a prior history of 
pre-morbid psychiatric problems prior to the injury is also a 
risk factor for depression after the injury (Bowen et al. , 1998; 
Rao et al., 2010; Rapoport, 2012). These findings suggest that 
some individuals, either due to genetics, age, injury, disease 
or psychosocial factors have a heightened or otherwise dys-
regulated response to inflammatory molecules. Thus, two 
hits - predisposition towards inflammation and an acute 
insult - could tip the balance towards the development of 
depression. 
The third line of evidence comes from clinical trials where 
anti-cytokine treatment has been shown to reduce depres-
sion compared to control groups. Much of this evidence 
comes from studies where anti-cytokine therapy was used 
for the treatment of autoimmune disorders, such as psori-
asis, rheumatoid arthritis, and Crohn's disease. As summa-
rized in a systematic review and meta-analysis (Kappelmann 
et al., 2018), anti-cytokine treatment was found to have a 
significant reduction in depression symptoms compared to 
placebo, across the 16 studies included in the analysis, with 
an effect estimate of 0.4. To date a single randomized con-
trolled trial has been completed using Infliximab, a TNFa-
blocking antibody, in treatment-resistant depression. While 
blocking TNFa showed no significant effect on reducing 
depression, a secondary analysis showed that in a subgroup 
of participants that had elevated C-reactive protein lev-
els (a protein associated with increases in inflammation), 
there was a significant effect of Infliximab treatment on 
depression symptoms (Raison et al., 2013). While not di-
rectly affecting cytokine signaling, other studies have found 
beneficial effects of adding nonsteroidal anti-inflammatory 
drugs (NSAIDs) to SSRI therapy (Kappelmann et al., 2018). 
NSAIDs, in addition to inhibition of prostaglandin syn-
thesis, are able to cross the cell membrane to block various 
signaling cascades important for the inflammatory response 
(Diaz-Gonzalez and Sanchez-Madrid, 2015) . Moreover, 
minocycline, an antibiotic with immunomodulatory proper-
ties, was shown in a recent meta-analysis to have significant 
antidepressant activity (Rosenblat and McIntyre, 2018). 
As depression is a complex disorder, with many different 
potential comorbidities, but common symptomology, there 
is a need to consider multiple theories for the pathogenic 
mechanisms of depression. With the evidence presented 
here, the inflammatory theory of depression shows great 
promise. As such, there are currently a number of active 
clinical trials investigating anti-cytokine interventions for 
the treatment of depression (NCT03004443, NCT03006393, 
NCT02765100, NCT02456948). While there has been ample 
evidence of the involvement of cytokines following TBI and 
a link with post-traumatic depression, there is currently no 
information available about active or completed trials using 
anti-cytokine treatment for depression following a TBI. 
Neuromodulatory Mechanism of TNFa and 
IL-1 ~ in Regulating Synaptic Function 
Beyond their role in immune function, cytokines have nu-
merous roles in regulating neuronal function, which occur 
at the synapse (Figure 2). What is telling about the impor-
tance of cytokines as neuromodulators, is the highly specific 
mechanisms by which cytokines alter the function of differ-
ent subsets of neurons. For instance, high levels of IL-1 and 
TNFa have been shown to impair long-term potentiation 
(LTP) induction and maintenance, but low levels of IL-1 
and TNFa are necessary for L TP induction and mainte-
nance (Murray and Lynch, 1998; Ross et al., 2003; Stell-
wagen and Malenka, 2006; Mori et al. , 2014). Further, and 
specifically relevant for the role of cytokines in depression, 
IL-1 and TNFa have important roles in serotonergic signal-
ing (Ramamoorthy et al., 1995; Mossner et al., 1998; Zhu et 
al., 2005, 2006, 2010; Steiner et al., 2008) (Figure 2). These 
cytokines have been shown to directly regulate the serotonin 
transporter (SERT) through a mechanism dependent on 
p38 mitogen activated protein kinase (MAPK) pathway, via 
increased production of SERT and increased localization of 
SERT to the membrane (Ramamoorthy et al., 1995; Mossner 
et al., 1998; Zhu et al., 2005, 2006, 2010; Steiner et al., 2008) 
(Figure 2B). 
The effects of cytokines on neuronal modulation are 
concentration dependent, where physiological levels of cy-
tokines are necessary to facilitate memory formation (V ez-
zani and Viviani, 2015). Acute increases in cytokines may 
increase awareness and sensory functions (Liu and Quan, 
2018), while chronic increases cytokines impair synaptic 
function (Rogers et al., 2011; Bachstetter et al., 2012; Furman 
et al., 2012). What follows is a review of the mechanisms by 
which TNFa and IL-1 have been shown to modulate neuro-
nal function at the synapse. 
TNFa is produced as a transmembrane protein that can 
be cleaved from the membrane by TNFa converting en-
zyme (also known as ADAM17) to produce a soluble cyto-
kine. TNFa signals via two membrane receptors, TNFRl 
and TNFR2. The ubiquitously expressed tumor necrosis 
factor receptor (TNFR)l can bind both the soluble and 
membrane-bound forms of TNFa. TNFRl is implicated in 
apoptotic, proinflammatory, and pathological processes, as 
well as neuronal signaling, in response to TNFa activation 
(Konefal and Stellwagen, 2017). TNFR2 has a restricted 
expression, in comparison to TNFRl, and is found on endo-
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Figure I The effect of traumatic brain injury (TBI) on acute cytokine response, and chronic cytokine dysregulation. 
(a) A TBI causes local reactive microglia/macrophages and astrocytes (b). Humoral, cellular, and neural routes (c) lead to increase in local and sys-
temic cytokines. The profile of the different cytokines (for example, interleukin (IL)-I, IL-6, and tumor necrosis factor a (TNFa)), indicated by the 
blue, orange, and green dots, have slightly different temporal patterns and max amplitude, but in general, follow a similar profile. (d) The acute in-
flammatory response to injury results in a surge of cytokines within the first hours-to-days after injury, which can be easily detected by biomarker 
assays (pink box). After the first week post-injury (e), cytokines fall below the level of sensitivity for most biomarker assays, but potentially remain 
above physiological levels (green box). Compounding factors, such as psychosocial stress and infection, may result in secondary spikes in inflam-
matory cytokines as measured in biomarker assays (f). Regardless, of the ability to measure cytokines in biomarker assays, therapeutically targeting 
the chronic dysregulated cytokines during the months-to-years after injury (g), could reduce cognitive, psychological, and physical complications 
of a TBI. Future studies are warranted to test this prediction. However, as cytokines have essential physiological functions, it will be necessary to 
have selective therapeutics that restore the physiological balance of cytokines, and not pan-immune suppression. 
A 
glutamate and GABA 
s'gnaling 
B C 
monoamine metabolism synapse formation 
and stabilization 
Figure 2 Mechanisms by which interleukin I (IL-I) and tumor necrosis factor (TNF) can directly regulate neuronal synaptic function. 
(A) IL-1 and TNFa regulate the excitatory and inhibitory neurotransmitter balance. Hyperphysiological levels of cytokines, such as following 
a traumatic brain injury (TBI) , increase excitatory (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMAPR) and N-meth-
yl-D-aspartic acid receptor (NMDAR)) neurotransmission, while decreasing inhibitory (y-aminobutyric acid (GABA) A receptor (GABAAR)) 
neurotransmission. Cytokines can also affect the release of glutamate (Glu) from neurons, and the uptake and release of glutamate from astro-
cytes. (B) IL-I and TNFa also increase the activity of the serotonin transporter (SERT), leading to a decrease in serotonin (5-HT) at the synapse. 
( C) Members of the IL- I family of proteins are also involved in synapse formation and stabilization, and IL- I signaling can regulate this process. 
EAAT2: Excitatory amino acid transporter 2; IL-IRI : IL-I receptor I; IL-IRAPLI : IL-I-receptor accessory protein like I; IL-IRAcP: IL-I receptor 
accessory protein; TNFRl: TNF receptor l; JNK: c-Jun terminal kinase; system :xc·: cystine/glutamate antiporter system. 
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thelial cells, immune cells, and some neuronal populations 
(McCoy and Tansey, 2008). TNFR2 is implicated in prosur-
vival, and immune suppression. The membrane-bound form 
ofTNFa is the most potent activator ofTNFR2 (Grell et al., 
1995). Following brain and spinal cord injury, TNFR2 has 
been shown to be neuroprotective and promote regenera-
tion (Sullivan et al., 1999; Mironets et al., 2018). The effects 
of TNFa on synaptic function are thought to occur through 
TNFRl signaling (Stellwagen et al., 2005; Pribiag and Stell-
wagen, 2013). 
In the hippocampus, TNFa has significant effects on 
glutamate signaling, by altering the expression, composi-
tion, and phosphorylation of a-amino-3-hydroxy-5-meth-
yl-4-isoxazolepropionic acid receptor (AMPAR), which 
effect duration of AMP AR-mediated spontaneous excitatory 
postsynaptic currents (Bernardino et al., 2005; Stellwagen 
et al. , 2005; Lai et al., 2006; Stellwagen and Malenka, 2006; 
Leonoudakis et al., 2008; Sama et al. , 2012; Mandolesi et al., 
2013). The effects ofTNFa on AMP AR activity appear to be 
concentration and exposure length dependent. For exam-
ple, following acute exogenous exposure of TNFa, a rapid 
increase in AMP AR surface expression and activity have 
been reported (Beattie et al., 2002; Stellwagen et al., 2005; 
Stellwagen and Malenka, 2006). In contrast, chronic expo-
sure to low levels of TNFa, as in the case of normal aging, 
decreases AMPARs (Sama et al., 2012). Mechanistically, the 
regulatory effects of TNFa on AMP ARs has been proposed 
to occur via phosphatidylinositol 3-kinase (PBK), and p38 
MAPK (Pribiag and Stellwagen, 2014) (Figure 2A). Howev-
er, the full signal transduction pathway regulating the effects 
of TNFa on AMP AR remains to be defined. The effects of 
TNFa on glutamate signaling appear to be independent of 
the N-methyl-D-aspartic acid receptor (NMDAR), at least in 
the context of acute TNFa exposure (Beattie et al., 2002; He 
et al., 2012), and in the context of chronic TNFa seen with 
healthy aging (Sama et al., 2012). 
In addition to the effects that TNFa has on the excitato-
ry neurotransmission, via the AMP AR, TNFa also effects 
y-aminobutyric acid (GABA) A receptor (GABAAR). GAB-
AAR is the principal mediator of inhibitory neurotrans-
mission in the brain. Specifically, TNFa, acting on neurons 
causes a rapid internalization of GABAAR, which decreases 
the inhibitory synaptic strength (Pribiag and Stellwagen, 
2013). The signal transduction pathway regulating the effects 
of TNFa on GABAAR also requires p38 MAPK and PI3K 
(Pribiag and Stellwagen, 2013) (Figure 2A). 
The IL-1 family includes two agonists, IL-la and IL-1~, 
which bind to the same receptor (IL-lRl), to cause a similar 
biological response. IL- la is released by all cells, when in-
jured or dying, to rapidly activate an inflammatory response. 
IL-1~ is mainly produced by immune cells and microglia. 
IL-1R2 is a decoy receptor not capable of signaling. In the 
brain, an alternative promoter in the IL- lRl gene generates 
a functional brain-specific IL-1 receptor called, IL-1R3 (Qian 
et al., 2012). IL-lRl is most highly expressed in the brain on 
endothelial cells, and neurons (Liu et al., 2015). The canon-
ical IL-lRl signaling pathway requires the IL- lRl accessory 
protein subunit (AcP). In the brain, an alternative IL- lRl 
co-receptor, called AcPb, was recently identified (Smith et 
al., 2009; Huang et al., 2011). IL-lRl and the IL-lRl acces-
sory proteins (AcP, and AcPb) are highly expressed at the 
neuronal synapse (Prieto et al., 2015). 
At the postsynaptic terminal, similar to TNFa, IL-1 has 
been shown to regulate AMP A receptor expression, phos-
phorylation, and activity (Stellwagen et al., 2005; Lai et al., 
2006; Kawasaki et al. , 2008; Mandolesi et al., 2013; Machado 
et al., 2018; Tong et al., 2018). In contrast to TNFa, IL-1 
has also been found to have significant effects on NMDAR. 
IL-I-induces phosphorylation of the NR2A/B subunits 
of the NMDAR, as well as altering the cellular localiza-
tion of AMP AR and NMDAR, via a Src kinase-dependent 
mechanism (Viviani et al., 2003; Davis et al., 2006a, b; San-
chez-Alavez et al., 2006; Ghosh et al., 2016; Bertani et al., 
2017; Tong et al., 2018) (Figure 2A). IL-lRl has also been 
shown to be physically associated with NR2B (Gardoni et al., 
2011), further illustrating the interaction between IL-1 and 
modulating activity at the synapse. Also, at the postsynaptic 
terminal, chronic IL-1/IL- lRl signaling pathway reduces 
GABAAR-mediated inhibitory postsynaptic currents (Kawa-
saki et al., 2008; Roseti et al., 2015), which reduces the coun-
terbalance to the excitatory glutamatergic signaling, while 
acute stimulation with IL-1 increases membrane expression 
of GABAAR, via an AKT and p38 dependent pathway (Ser-
antes et al., 2006; Wang et al., 2012). 
At the presynaptic terminal, IL-1 can increase the release 
of glutamate (Casamenti et al., 1999). Astrocytes that sur-
round the synapse are also involved in the IL-1 dependent 
regulation of glutamate signaling (Figure 2A). IL-1 decreas-
es uptake of extracellular glutamate, via a reduction in the 
high-affinity glutamate transporters on the astrocyte, glial 
glutamate transporter I/excitatory amino acid transporter 
2 (GLT1/EAAT2). The reduction in GLT1/EAAT2 occurs 
through enhanced endocytosis, by a calcium/PKC depen-
dent mechanism (Mandolesi et al., 2013; Yan et al., 2014b). 
Also at the astrocyte, IL-1 increases the activity of the cys-
tine/ glutamate antiporter System Xe·, leading to increased 
release of glutamate from astrocytes (Fogal et al., 2007). 
Physical interaction between pairs of presynaptic and 
postsynaptic adhesion molecules is known to regulate syn-
apse formation and stabilization (Takahashi and Craig, 
2013; Thalhammer and Cingolani, 2014). Currently, less 
than ten postsynaptic adhesion molecules have been identi-
fied. Interestingly, three of the postsynaptic adhesion mol-
ecules belong to the IL-1 family. Specifically, IL-1 receptor 
1 accessory protein (IL-lRlAcP) and IL-lRlAcPb, as well 
as IL- I -receptor accessory protein like 1 (ILl RAPLl) are 
important postsynaptic adhesion molecules, which interact 
physically with protein tyrosine phosphatase (PTP) l5 to reg-
ulate synaptogenesis and spine stabilization (Yoshida et al., 
2012; Yamagata et al., 2015; Pozzi et al., 2018). IL-1 has been 
shown to alter dendritic morphology by signaling through 
the IL-lRlAcP(b)/IL-lRlAPLl complex, through a c-Jun 
terminal kinase (JNK) pathway (Pavlowsky et al., 2010; 
Montani et al., 2017) (Figure 2C). 
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When Can Cytokines Be Targeted 
Therapeutically after a TBI? 
Following fundamental principles of pharmacology, it is 
often assumed that it is necessary to target cytokines after 
an injury during the peak of their response, or at least while 
they are elevated above basal levels. As described, the peak 
of cytokines occurs within hours to a day after an injury; 
thus, it can be difficult to target cytokines clinically during 
this short window. However, blocking cytokines during the 
first hours after injury, could prevent the onset of chronic 
neuroinflammation, and block excitatory damage to neu-
rons occurring through dysregulation of the glutamate and 
GABA signaling (Figure 2). 
As described, in blood and CSF, levels of cytokines stabilize 
at or near physiological levels within a week in people after 
a brain injury. Similarly, in animal models of TBI, cytokine 
levels in brain homogenates return to sham-injured levels 
typically within a week (Bachstetter et al., 2013, 2015; Web-
ster et al., 2015). These data would suggest that the effect of 
cytokines in the long-term neurological sequelae of the TBI, 
is over after the first week of the injury, and treatments that 
target cytokines should be used during this period after the 
injury. However, we demonstrated in a mouse model of TBI, 
that we could promote functional recovery in a learning and 
memory task when we started the treatment with a small 
molecule cytokine inhibitor one week after the injury (Web-
ster et al., 2015). These data suggest that there are likely local 
disruptions in the cytokine signaling network, possibly occur-
ring at the synapse following a TBI, which last much longer 
than would be predicted by the biomarker data (Figure 1). 
As cytokines act in an autocrine and paracrine manner in 
the local tissue milieu, it may not be possible using existing 
technology to see changes in the cytokines following TBI at 
the circuit level, specifically at the synapse. Neurons, for in-
stance, are 1000 times more sensitive to IL-1, than other cell 
types (Huang et al., 2011), so that even changes in IL-1 levels 
that are too small to detect with current methods, could have 
a profound impact on neuronal physiology. An alternative 
hypothesis is that the primary injury or acute cytokine re-
sponse to the injury increases the sensitivity of cells to the 
cytokines so that low amounts of cytokines are producing an 
exaggerated response in the injured brain compared to the 
uninjured brain (Figure 1). Much more work is warranted 
to test these potential mechanisms. Low levels of chronic 
cytokine dysregulation are associated with depression, and 
clinical evidence has demonstrated that reducing cytokine 
signaling has a significant impact on depression (Raison et 
al., 2013; Kappelmann et al., 2018). 
Animal models of CNS injury have had mixed success in 
modeling psychiatric symptoms following a TBI, such as 
depressive-like symptoms using tasks such as the forced-
swim test and sucrose preference test, as only a few studies 
have been able to detect depressive-like symptoms after the 
brain injury (Milman et al., 2005; Jones et al., 2008; Mal-
kesman et al., 2013; Fenn et al., 2014, 2015; Petraglia et al. , 
2014; Wu et al., 2014; Rowe et al. , 2016; Lim et al., 2017a, b; 
Tucker et al. , 2017). However, depressive-like symptoms in 
animal models are likely associated with periods of remis-
sion and reestablishment, as seen in people. Moreover, as in 
people, animal models may require a secondary challenge 
for the TBI-induced depressive-like symptoms to be evident. 
For example, an eloquent study found that a subsequent 
immune challenge in mice, after the TBI-induced depres-
sive-like behavior had resolved, caused reestablishment of 
the depressive-like symptoms (Fenn et al., 2014). As illus-
trated in Figure 1, during the chronic phase after the brain 
injury, a secondary challenge to the system, which has been 
primed by the TBI can lead to psychiatric and neurodegen-
erative conditions (for a review on inflammatory priming 
(Witcher et al. , 2015)). 
Conclusions 
As a multifaceted disorder, depression has been associated 
with many medical conditions, including diabetes, cancer, 
and cardiovascular disease, as well as TBI, and Alzhei-
mer's disease (Lang and Borgwardt, 2013). The biological 
underpinnings of depression are not fully understood and 
how depression interacts with these different diseases is a 
significant topic of study. For approximately one-third of 
people with depression, conventional antidepressants are 
not effective. Specifically, in major depression after a TBI, 
as described earlier, there are conflicting results on the ef-
fectiveness of SSRis (Jorge et al., 2016; Fann et al., 2017). 
In these individuals, alternative methods of treatment have 
been proposed to individualize treatments to find the most 
effective pharmacotherapy to alleviate their symptoms. One 
such effort to predict response used computer modeling to 
improve the likelihood of treatment efficacy (Chekroud et 
al., 2016). Animal models have provided further evidence 
that increasing and decreasing inflammation after a TBI can 
have a reciprocal effect on depressive-like behavior (Fenn et 
al., 2014, 2015). 
There are numerous theories for biological mechanisms 
of depression (Belmaker and Agam, 2008) . Following at 
least thirty years of research since the macrophage theory 
of depression was initially postulated (Smith, 1991), there is 
now mounting evidence demonstrating that inflammatory 
pathways contribute to the pathophysiology of depressive 
disorders (Dantzer et al., 2008; Miller and Raison, 2016). As 
cytokine dysregulation is a hallmark pathology of TBI, the 
inflammatory theory of depression is particularly relevant to 
mood disorders that develop following a TBI. Determining 
how cytokines regulate mood is an exciting area of investi-
gation and may have great potential for treating mood dis-
orders in people that suffered a TBI. 
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